Optimizing Hypomethylating Therapy in Myelodysplastic Syndromes

Explore the latest advancements in oral hypomethylating agents for MDS and CMML, emphasizing their efficacy, patient convenience, and treatment strategies.

Explore the differences between bispecific antibodies and CAR T-cell therapy, highlighting their unique benefits and administration processes in cancer treatment.

Explore the differences between bispecific antibodies and CAR T-cell therapy, highlighting their unique benefits and administration processes.

Explore the practical challenges of using oral hypomethylating agents, focusing on safety, access, and effective patient management strategies.

This segment explores the critical role of patient support programs, insurance navigation, and balancing the convenience of oral HMAs with ongoing clinical oversight.

This case-based discussion illustrates the practical management of a 72-year-old patient with high-risk MDS and TP53 mutation.

This segment continues the discussion of high-risk MDS management, focusing on how clinicians define failure of HMAs and determine next steps in therapy, particularly in patients with TP53 mutations.

The panel discusses the case of a 67-year-old female patient diagnosed with high-risk chronic myelomonocytic leukemia (CML-1) who presents with intermediate risk scores and abnormal blood counts, including elevated white blood cells, mild thrombocytopenia, and anemia.

This segment focuses on practical strategies for managing high-risk CML, particularly in patients with proliferative and cytopenic symptoms. The discussion begins with balancing symptomatic management, such as fatigue, early satiety, splenomegaly, anemia, and thrombocytopenia, alongside disease-directed therapy.

In this concluding segment, the panel reflects on the evolving landscape of treatment for myeloid malignancies, including high-risk MDS and CML, with a focus on oral HMAs. Dr. Fazal emphasizes the importance of clinical trial participation, noting that although some combination therapies may not show overall superiority, subsets of patients demonstrate meaningful benefit, highlighting the need for ongoing research and novel therapeutic strategies.